The development of predictive preclinical assays is key to success in drug development. It is therefore critical to carefully construct biomarker studies using the most appropriate assays that better represent the complex physiology of disease for the reliable assessment of safety, efficacy, and dose predictions.
To explore this topic further, Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases, Takeda Pharmaceuticals will be discussing translational immuno-oncology assay development in an upcoming webinar on May 26.
This webinar, Enhancing the predictability of preclinical development, hosted by DDW and supported by PerkinElmer, will take place on 26 May at 4PM BST; 8AM PDT; 11 AM EDT; 5PM CEST.
Dr. Cho will provide examples of multiple pre-clinical assays she has used, including cultured human primary immune cell-based assays and patient-derived 3D organoid assays.
The session will also include a talk from Dr. Seyoum Ayehunie, Vice President, Scientific Research and Development, MatTek Corporation, who will discuss the functionality and limitations of a novel in vitro 3D primary human cell-based tissue model for drug toxicity and efficacy studies.
Key Learning Objectives:
- How to evaluate models to establish robust and reliable preclinical investigation of drug candidates prior to entering clinical trials
- How to gain an understanding of the advancements in preclinical model systems and assays
- What to consider from the latest innovations and impact on bioanalytical assays
Who Should Attend:
- Preclinical development scientists
- Bioanalytical assay development scientists
- Analytical scientists